1. A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY. (12th June 2019) Authors: Mato, A.R.; Schuster, S.J.; Lamanna, N.; Pagel, J.M.; Flinn, I.W.; Barrientos, J.; Reeves, J.A.; Cheson, B.D.; Barr, P.M.; Kambhampati, S.; Lansigan, F.; Pu, J.J.; Skarbnik, A.; Fonseca, G.; Dorsey, C.; LaRatta, N.M.; Weissbrot, H.; Svoboda, J.; Luning Prak, E.T.; Tsao, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. (June 2017) Authors: Nastoupil, L.; Lunning, M.A.; Vose, J.M.; Schreeder, M.T.; Siddiqi, T.; Flowers, C.R.; Cohen, J.B.; Burger, J.A.; Wierda, W.G.; O'Brien, S.; Sportelli, P.; Miskin, H.P.; Purdom, M.A.; Weiss, M.S.; Fowler, N.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA. (June 2017) Authors: Lunning, M.A.; Vose, J.M.; Bierman, P.J.; Bociek, G.; Schreeder, M.T.; Siddiqi, T.; Blumel, S.M.; Cutter, K.; Pauli, E.K.; Bui, D.; Sportelli, P.; Miskin, H.P.; Purdom, M.; Weiss, M.S.; Fowler, N.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. (12th June 2019) Authors: Mato, A.R.; Svoboda, J.; Luning Prak, E.T.; Schuster, S.J.; Tsao, P.Y.; Dorsey, C.; Sarmasti, L.M.; Becker, P.S.; Brander, D.M.; Nasta, S.; Landsburg, D.J.; King, C.M.; Morrigan, B.; Elwell, J.; Kennard, K.; Roeker, L.; Zelenetz, A.D.; Purdom, M.; Paskalis, D.; Sportelli, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THE NOVEL BISPECIFIC CD47‐CD19 ANTIBODY TG‐1801 POTENTIATES THE ACTIVITY OF UBLITUXIMAB‐UMBRALISIB (U2) DRUG COMBINATION IN PRECLINICAL MODELS OF B‐NHL. (12th June 2019) Authors: Normant, E.; Ribeiro, M.L.; Reyes, D.; Miskin, H.P.; Sportelli, P.; Weiss, M.S.; Bosch, F.; Roue, G. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY. (June 2017) Authors: Sharman, J.P.; Brander, D.M.; Mato, A.; Kambhampati, S.; Burke, J.M.; Lansigan, F.; Schreeder, M.T.; Lunin, S.D.; Ghosh, N.; Zweibach, A.; Shtivelband, M.I.; Travis, P.M.; Chandler, J.; Kolibaba, K.S.; Sporteli, P.; Miskin, H.P.; Weiss, M.S.; Flinn, I.W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY. (12th June 2019) Authors: Zinzani, P.; Samaniego, F.; Jurczak, W.; Lech‐Maranda, E.; Ghosh, N.; Anz, B.; Patten, P.; Reeves, J.; Leslie, L.A.; Smolewski, P.; Chavez, J.C.; Scarfo, L.; Derenzini, E.; Burke, J.M.; Sharman, J.; Kolibaba, K.; O'Connor, O.A.; Cheah, C.Y.; Miskin, H.P.; Sportelli, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗